Attrition among human immunodeficiency virus (HIV)- infected patients initiating antiretroviral therapy in China, 2003-2010

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Zhu, Hao ^a,c   Napravnik, Sonia ^a,b   Eron, Joseph ^a,b   Cole, Stephen ^a   Ma, Ye ^c   Wohl, David ^b   Dou, Zhihui ^c   Zhang, Yao ^c   Liu, Zhongfu ^c   Zhao, Decai ^c   Cohen, Myron ^a,b   Zhang, Fujie ^c,d  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS DIDANOSINE; EFAVIRENZ PLUS LAMIVUDINE; EFAVIRENZ PLUS NEVIRAPINE; EFAVIRENZ PLUS STAVUDINE; EFAVIRENZ PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE; NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CD4+ T LYMPHOCYTE; CHINA; CONTROLLED STUDY; DIVORCE; FEMALE; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NATIONAL FREE ANTIRETROVIRAL TREATMENT PROGRAM; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTION; SEX DIFFERENCE; SOCIAL STATUS; TREATMENT DURATION; TREATMENT INDICATION; TREND STUDY;

AGE FACTORS; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHINA; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; PATIENT DROPOUTS; SEX FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84862987042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039414     Document Type: Article

References (40)

1. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, et al. (2006) The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368: 505-510.
2. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449-457.
3. Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, et al. (2010) Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 11: 516-524.
4. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, et al. (2009) Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 151: 241-251, W-252.
5. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
6. ART Cohort Collaboration, (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
7. Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, et al. (2008) Loss to follow-up in an international, multicentre observational study. HIV Med 9: 261-269.
8. Maskew M, MacPhail P, Menezes C, Rubel D, (2007) Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 97: 853-857.
9. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86: 559-567.
10. MacPherson P, Moshabela M, Martinson N, Pronyk P, (2009) Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg 103: 588-593.
11. Chasombat S, McConnell MS, Siangphoe U, Yuktanont P, Jirawattanapisal T, et al. (2009) National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 50: 506-512.
12. Karcher H, Omondi A, Odera J, Kunz A, Harms G, (2007) Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 12: 687-694.
13. Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, et al. (2006) Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol 59: 829-835.
14. Brinkhof MW, Pujades-Rodriguez M, Egger M, (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 4: e5790.
15. Mugavero MJ, Norton WE, Saag MS, (2011) Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis 52: S238-246.
16. Mugavero MJ, Lin HY, Willig JH, Westfall AO, Ulett KB, et al. (2009) Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 48: 248-256.
17. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
18. UNAIDS (2010) Report on the Global AIDS Epidemic Joint United Nations Programme on HIV/AIDS, Geneva.
19. (2007) State Council AIDS Working Committee Office, UN Theme Group on HIV/AIDS in the People's Republic of China. A Joint Assessment of HIV/AIDS Prevention, Treatment, and Care in China: Beijing.
20. Zhang F, Dou Z, Yu L, Xu J, Jiao JH, et al. (2008) The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 47: 825-833.
21. Dou Z, Chen RY, Wang Z, Ji G, Peng G, et al. (2010) HIV-infected former plasma donors in rural Central China: from infection to survival outcomes, 1985-2008. PLoS One 5: e13737.
22. Ma Y, Zhang F, Zhao Y, Zang C, Zhao D, et al. (2009) Cohort profile: the Chinese national free antiretroviral treatment cohort. Int J Epidemiol 39: 973-979.
23. Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y, (2005) Current progress of China's free ART program. Cell Res 15: 877-882.
24. Zhang F, (2008) China Free Antiretroviral Therapy Manual, 2008 Edition.
25. Dou Z, Chen RY, Xu J, Ma Y, Jiao JH, et al. (2010) Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09. Int J Epidemiol 39: ii56-64.
26. Ekouevi DK, Balestre E, Ba-Gomis FO, Eholie SP, Maiga M, et al. (2010) Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health 15: 34-42.
27. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, et al. (2010) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405-411.
28. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN, (2008) Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. Jama 300: 506-507.
29. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, et al. (2006) Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 43: 770-776.
30. Geng EH, Nash D, Kambugu A, Zhang Y, Braitstein P, et al. (2010) Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep 7: 234-244.
31. Chan AK, Mateyu G, Jahn A, Schouten E, Arora P, et al. (2010) Outcome assessment of decentralization of antiretroviral therapy provision in a rural district of Malawi using an integrated primary care model. Trop Med Int Health 15: 90-97.
32. Bedelu M, Ford N, Hilderbrand K, Reuter H, (2007) Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 196: S464-468.
33. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, et al. (2007) True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 85: 550-554.
34. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, et al. (2008) Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One 3: e1725.
35. Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, et al. (2008) Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr 47: 101-107.
36. Zachariah R, Van Engelgem I, Massaquoi M, Kocholla L, Manzi M, et al. (2008) Payment for antiretroviral drugs is associated with a higher rate of patients lost to follow-up than those offered free-of-charge therapy in Nairobi, Kenya. Trans R Soc Trop Med Hyg 102: 288-293.
37. Liu J, Fan D, (2007) Hepatitis B in China. Lancet 369: 1582-1583.
38. Matthews G, (2007) The management of HIV and hepatitis B coinfection. Curr Opin Infect Dis 20: 16-21.
39. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
40. Liao L, Xing H, Shang H, Li J, Zhong P, et al. (2010) The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 53: S10-14.